TScan Therapeutics TCRX
NASDAQ TCRX
$0.20 -0.02 (-9.09%)
At close: Oct 23, 2026 · 4:00 PM EDT

TScan Therapeutics (TCRX) Receivables (2023)

Updated

TScan Therapeutics' Receivables came in at $31.93 million for Q2 2023.

Analysis

TScan Therapeutics (TCRX) Receivables (2023) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Receivables (Qtr)
1 Eli Lilly 1,199.50 Bn 1,168.08 Bn 19.71 Bn 23.48 Bn
2 Johnson & Johnson 635.17 Bn 555.03 Bn 17.30 Bn 18.99 Bn
3 AbbVie 504.69 Bn 477.85 Bn 12.70 Bn 13.82 Bn
4 Merck 358.43 Bn 312.86 Bn 12.21 Bn 12.56 Bn
5 Novartis Ag 288.36 Bn 252.75 Bn 11.24 Bn 9.64 Bn
6 Astrazeneca 265.78 Bn 239.54 Bn 12.86 Bn 15.68 Bn
7 Amgen 237.46 Bn 192.86 Bn 7.24 Bn 10.23 Bn
8 Gilead Sciences 193.65 Bn 167.76 Bn 6.22 Bn 5.06 Bn
9 Pfizer 171.05 Bn 118.00 Bn 10.94 Bn 12.49 Bn
10 TScan Therapeutics 25.99 Mn -539.13 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 31.93 Mn
API Access

TScan Therapeutics Receivables API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=receivables&ticker=TCRX&period=max&api_key=YOUR_API_KEY